Keyphrases
Virus
100%
Venezuelan Equine Encephalitis Virus
80%
COVID-19
72%
Alphavirus
69%
Junin Virus
63%
Lassa Virus
63%
Virus Infection
62%
Lassa Fever
47%
Arenavirus
41%
Encephalitis
35%
Glycoprotein
35%
Machupo Virus
32%
Eastern Equine Encephalitis Virus
26%
Argentine Hemorrhagic Fever
26%
Influenza Virus
25%
Recombinant
25%
Attenuation
25%
Hearing Impairment
24%
Venezuelan Equine Encephalitis
23%
New World Arenavirus
22%
Antiviral Activity
22%
Repurposing
22%
Murine Model
22%
Virus Strains
22%
Vaccine Development
20%
Highly Pathogenic
20%
Lethal Infection
19%
Guinea pig
19%
TC83
19%
Live Attenuated
18%
Interferon-α (IFN-α)
18%
Vaccine Candidate
18%
Ebola Virus
18%
Immunogenic
17%
Mouse Model
17%
Viral Infection
17%
Virus Replication
16%
Eastern Equine Encephalitis
16%
Vaccine Strain
16%
Epizootic
16%
Viremia
15%
In Silico
15%
Causative Agents
15%
South America
15%
West Africa
15%
H5N1
15%
Zika Virus
15%
Sudden Sensorineural Hearing Loss (SSNHL)
14%
Immune Response
14%
Enzootic
14%
Immunology and Microbiology
Viral Disease
77%
Alphavirus
66%
Hemorrhagic Fever
63%
Venezuelan Equine Encephalitis Virus
61%
Junin Virus
58%
Lassa Virus
55%
Glycoprotein
52%
Encephalitis
51%
Severe Acute Respiratory Syndrome Coronavirus 2
39%
Machupo Virus
37%
interferon
36%
Eastern Equine Encephalitis Virus
31%
Arenaviridae
30%
Equus
29%
Gel Permeation Chromatography
28%
New World Arenavirus
25%
Immune Response
23%
Arenavirus
22%
Infectious Agent
21%
Neutralizing Antibody
19%
Viral Replication
19%
Central Nervous System
18%
Influenza
18%
Immunology
18%
Influenzavirus A
18%
T Cell
17%
Attenuated Vaccine
14%
Live Vaccine
14%
COVID-19
14%
Influenza A Virus (H5N1)
14%
Virus Strain
14%
Guinea Pig
14%
Virus Vaccine
14%
Mouse Model
13%
T-Helper Cell
13%
Innate Immune System
13%
Cell Culture
12%
Western Equine Encephalitis Virus
11%
Sindbis Virus
11%
Ebola Virus
11%
Influenza Virus
11%
Hemagglutinin
11%
Viremia
10%
Pattern Recognition Receptor
10%
Influenza A Virus (H1N1)
10%
RNA Virus
10%
Glycosylation
10%
Precursor
10%
Wild Type
9%
RIG-I
9%